ALKS vs CBRE · P/E 14, rev $1.56B vs P/E 43, rev $35.77B
Alkermes Plc (ALKS) versus CBRE Group Inc Class A (CBRE) — a side-by-side from cached financials, not a winner call.
Alkermes Plc (ALKS) is a drug manufacturers - specialty & generic company listed on US.
CBRE Group Inc Class A (CBRE) is a real estate services company listed on US.
Latest reported ALKS revenue for 2024-12-31 was $1.56B. Net income was $367.1M. Revenue was down 6.4% from 2023-12-31 to 2024-12-31. ALKS currently screens at market cap $4.78B and trailing P/E 13.8.
Latest reported CBRE revenue for 2024-12-31 was $35.77B. Net income was $1.04B. Revenue was up 12.0% from 2023-12-31 to 2024-12-31. CBRE currently screens at market cap $41.66B and trailing P/E 42.7.
ALKS currently screens at market cap $4.78B and trailing P/E 13.8. CBRE currently screens at market cap $41.66B and trailing P/E 42.7.
Not investment advice. Open the ALKS and CBRE stock pages for the full models.
Not investment advice.